As hepatitis B research progresses, achieving higher functional cure rates is becoming more feasible. It is vital that ...

GlobalData expects the chronic hepatitis B therapeutics market across major markets to climb from $1.5 billion in 2024 to ...

A recent study published in Alimentary Pharmacology and Therapeutics reports that patients with a lower hepatitis B virus (HBV) haplotype number of less than or equal to two are more likely to achieve ...

Despite untreated HBV being linked to earlier mortality, higher all-cause and liver-related death, and a 10% to 25% lifetime risk of developing hepatocellular carcinoma (HCC), only 29% of qualifying ...

Hepatitis B virus (HBV) is a significant public health problem, with over 296 million people chronically infected worldwide. Despite the availability of a safe and effective vaccine for over 40 years, ...

There is a lack of data supporting the notion that antiviral treatments can benefit children with chronic hepatitis B (CHB) having high viremia and normal or mildly elevated serum alanine ...

Antiviral treatments play a crucial role in the survival of patients with either hepatitis B or C and liver cancer, but researchers have found that antiviral therapy is “severely underutilized” even ...

Chronic hepatitis B occurs when the body cannot eliminate the hepatitis B virus following an acute infection. Having chronic (or lifelong) hepatitis B can increase a person’s risk of developing ...

Hepatitis B vaccines given at birth have essentially eliminated the disease in kids. A vote this week could upend that ...

New Delhi: According to the World Health Organization (WHO), viral hepatitis has now become as deadly as tuberculosis. Every 30 seconds, someone in the world dies of viral hepatitis. The WHO’s 2024 ...

As RFK Jr.'s new vaccine panel ponders changing the hepatitis B vaccination schedule, some doctors recall past patients, ...

Vaccine advisers to the US Centers for Disease Control and Prevention may vote this week to make a major change to the ...